<div id="readability-page-1"><p><strong>Artelo Biosciences, Inc. <span>( ARTL )</span></strong> shares jumped on Monday after the company announced the publication of a peer‑reviewed article highlighting FABP5 as a therapeutic target for pain. The move is drawing extra attention as broader markets edged lower, with the S&amp;P 500 down 0.4% and Healthcare slipping 0.30%.</p>    <ul> <li>Artelo Biosciences <span>( ARTL )</span> stock is showing exceptional strength. What’s fueling ARTL momentum?</li> </ul>    <h2>Artelo Highlights Peer-Reviewed Article On Pain Treatment</h2>    <p>Artelo Biosciences <span>( ARTL )</span> announced that a peer‑reviewed article focused on FABP5 as a therapeutic target for pain was published, putting a spotlight on its science and pipeline narrative. The update hit as Healthcare is currently a bottom-performing sector on the day, ranking 9 out of 11 sectors.</p>    <p>“This peer-reviewed publication strengthens the scientific foundation for ART26.12 and reinforces our view that FABP5 inhibition represents a novel mechanism of action with the potential to redefine the treatment of pain,” said <strong>Andrew Yates</strong>, Artelo’s chief scientific officer. </p>    <h2>ARTL Shares Trade Below Key Averages</h2>    <p>Artelo is still working to repair a longer-term downtrend, with the stock sitting far below its 200-day simple moving average (SMA), which often acts like a &#34;line in the sand&#34; for long-term trend followers. At $5.12, the stock is trading 24% below its 20-day SMA and 1.2% below its 100-day SMA, which leans bearish for short-term momentum while showing it's trying to stabilize in the intermediate term.</p>    <p>The moving average convergence divergence (MACD), a trend/momentum measure, remains bearish with the MACD line below the signal line, which typically aligns with sellers having the edge on follow-through. With support near $5.00 and resistance near $6.00, traders are watching whether the breakout attempt can hold above support rather than fading back into the prior range.</p>    <p>The 12-month return is -73.31%, which underscores how much downside the stock has absorbed over the past year. Even after recent swings, the stock remains much closer to its $2.96 52-week low than its $85.80 high, a setup that often keeps rallies choppy unless new catalysts keep arriving.</p>    <ul> <li><strong>Key Resistance</strong>: $6.00 — an area where rebounds have recently struggled to push through.</li>    <li><strong>Key Support</strong>: $5.00 — a level buyers have defended, and a key &#34;hold&#34; zone for the current move.</li> </ul>    <h2>ARTL Shares Rise On Monday</h2>    <p><strong>ARTL Stock Price Activity:</strong> Artelo Biosciences <span>( ARTL )</span> shares were up 8.56% at $4.82 at the time of publication on Monday, according to Benzinga Pro data.</p>    <p><em>Image: Shutterstock</em></p></div>

ARTL

<p>Artelo Biosciences, Inc. (NASDAQ:ARTL) shares rose 8.56% to $4.82 after the publication of a peer-reviewed article on FABP5 as a therapeutic target for pain. This announcement comes amid a broader market decline, with the S&P 500 down 0.4%. Despite the recent gains, ARTL is still below key moving averages, indicating a longer-term downtrend. The stock has a 12-month return of -73.31%, with key support at $5.00 and resistance at $6.00, as traders monitor its ability to maintain momentum.</p>

What's Behind The Rise In Artelo Biosciences Stock?